脂质代谢紊乱诊断与治疗中的挑战与机遇：新见解与未来展望
Challenges and Opportunities on Lipid Metabolism Disorders Diagnosis and Therapy: Novel Insights and Future Perspective.
作者信息
Fras Zlatko, Jug Borut, Penson Peter E, Rizzo Manfredi
机构信息
Centre for Preventive Cardiology, Department of Vascular Medicine, Division of Medicine, University Medical Centre Ljubljana, SI-1525 Ljubljana, Slovenia.
Chair of Internal Medicine, Medical Faculty, University of Ljubljana, SI-1000 Ljubljana, Slovenia.
出版信息
Metabolites. 2021 Sep 9;11(9):611. doi: 10.3390/metabo11090611.
Abstract
Dyslipidemia has been globally recognized, for almost seven decades, as one of the most important risk factors for the development and complications of atherosclerotic cardiovascular disease (ASCVD) [...].
摘要
近七十年来，血脂异常已被全球公认为动脉粥样硬化性心血管疾病（ASCVD）发生和并发症的最重要危险因素之一[...]。
相似文献
1
Challenges and Opportunities on Lipid Metabolism Disorders Diagnosis and Therapy: Novel Insights and Future Perspective.脂质代谢紊乱诊断与治疗中的挑战与机遇：新见解与未来展望
Metabolites. 2021 Sep 9;11(9):611. doi: 10.3390/metabo11090611.
2
Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.优化血脂异常管理以预防心血管疾病：关注风险评估和治疗选择。
Curr Cardiol Rep. 2019 Aug 5;21(9):110. doi: 10.1007/s11886-019-1175-z.
3
Characteristics of patients with dyslipidemia treated in routine care setting in China.中国常规护理环境下血脂异常患者的特征。
J Drug Assess. 2019 Oct 23;8(1):192-198. doi: 10.1080/21556660.2019.1684926. eCollection 2019.
4
Diabetic dyslipidemia: a case for aggressive intervention in the absence of clinical trial and cost effectiveness data.糖尿病血脂异常：在缺乏临床试验和成本效益数据的情况下进行积极干预的理由。
Can J Cardiol. 1995 May;11 Suppl C:24C-28C.
5
National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report.美国国家脂质协会血脂异常患者中心管理建议：第1部分——完整报告
J Clin Lipidol. 2015 Mar-Apr;9(2):129-69. doi: 10.1016/j.jacl.2015.02.003. Epub 2015 Apr 7.
6
Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.血管护理质量评估：临床医生对动脉粥样硬化性心血管疾病患者降脂治疗的依从性
Ann Vasc Surg. 2020 Nov;69:197-205. doi: 10.1016/j.avsg.2020.06.003. Epub 2020 Jun 15.
7
Obstructive sleep apnea combined dyslipidemia render additive effect on increasing atherosclerotic cardiovascular diseases prevalence.阻塞性睡眠呼吸暂停合并血脂异常对增加动脉粥样硬化性心血管疾病的患病率具有叠加效应。
Lipids Health Dis. 2016 May 26;15:98. doi: 10.1186/s12944-016-0267-7.
8
Is diabetes mellitus equivalent to atherosclerotic cardiovascular disease from a healthcare cost perspective? Insights from the Medical Expenditure Panel Survey: 2010-2013.从医疗成本角度来看，糖尿病等同于动脉粥样硬化性心血管疾病吗？来自医疗支出面板调查（2010 - 2013年）的见解。
Cardiovasc Endocrinol Metab. 2018 Aug 15;7(3):64-67. doi: 10.1097/XCE.0000000000000151. eCollection 2018 Sep.
9
[Essence of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan-2012 Version and Treatment Guide for Dyslipidemia 2013--Current Strategy for the Lipid Assessment].[日本动脉粥样硬化协会（JAS）日本动脉粥样硬化性心血管疾病诊断与预防指南2012版及血脂异常治疗指南2013——血脂评估的当前策略]
Rinsho Byori. 2014 Sep;62(9):878-83.
10
Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition.极高危动脉粥样硬化性心血管疾病（ASCVD）风险识别。
Curr Diab Rep. 2019 Jul 22;19(8):61. doi: 10.1007/s11892-019-1178-6.
引用本文的文献
1
The effectiveness of exercise snacks as a time-efficient treatment for improving cardiometabolic health in adults: a systematic review and meta-analysis.运动零食作为一种提高成人心血管代谢健康的省时疗法的有效性：一项系统评价和荟萃分析。
Front Cardiovasc Med. 2025 Aug 13;12:1643153. doi: 10.3389/fcvm.2025.1643153. eCollection 2025.
2
Effects of Cardiac Rehabilitation and Diet Counselling on Adherence to the Mediterranean Lifestyle in Patients after Myocardial Infarction.心脏康复和饮食咨询对心肌梗死后患者遵循地中海式生活方式的影响。
Nutrients. 2022 Sep 29;14(19):4048. doi: 10.3390/nu14194048.
3
Association between Lipoprotein Subfractions, Hemostatic Potentials, and Coronary Atherosclerosis.脂蛋白亚组分、止血潜能与冠状动脉粥样硬化的相关性。
Dis Markers. 2022 Aug 30;2022:2993309. doi: 10.1155/2022/2993309. eCollection 2022.
4
Cholesterol Metabolic Markers for Differential Evaluation of Patients with Hyperlipidemia and Familial Hypercholesterolemia.胆固醇代谢标志物用于鉴别高脂血症和家族性高胆固醇血症患者。
Dis Markers. 2022 Apr 21;2022:2008556. doi: 10.1155/2022/2008556. eCollection 2022.
5
Beneficial Effects of the Consumption of Hot-Water Extracts of Thinned Immature Mangos ( "Irwin") on the Hypertriglyceridemia of Apolipoprotein E-Deficient Mice.食用疏果未成熟芒果（“欧文”）热水提取物对载脂蛋白E缺陷小鼠高甘油三酯血症的有益作用。
Metabolites. 2022 Jan 25;12(2):116. doi: 10.3390/metabo12020116.
本文引用的文献
1
Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: Analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry.与心肌梗死后中、长期死亡率极高的心血管风险相关的危险因素：对三级心脏中心血脂异常治疗（TERCET）登记研究的分析。
Atherosclerosis. 2021 Sep;333:16-23. doi: 10.1016/j.atherosclerosis.2021.08.024. Epub 2021 Aug 13.
2
On the present and future role of Lp-PLA in atherosclerosis-related cardiovascular risk prediction and management.脂蛋白磷脂酶A在动脉粥样硬化相关心血管疾病风险预测与管理中的当前及未来作用
Arch Med Sci. 2020 Aug 20;17(4):954-964. doi: 10.5114/aoms.2020.98195. eCollection 2021.
3
Incretin-based therapies in 2021 - Current status and perspectives for the future.2021年基于肠促胰岛素的疗法——现状与未来展望
Metabolism. 2021 Sep;122:154843. doi: 10.1016/j.metabol.2021.154843. Epub 2021 Jul 30.
4
Nocebo/drucebo effect in statin-intolerant patients: an attempt at recommendations.他汀不耐受患者中的反安慰剂/安慰剂效应：制定建议的尝试。
Eur Heart J. 2021 Dec 14;42(47):4787-4788. doi: 10.1093/eurheartj/ehab358.
5
Current Choice for LDL-C Lowering in High-Risk CVD Patients Intolerant to Statins.他汀类药物不耐受的高危心血管疾病患者降低低密度脂蛋白胆固醇（LDL-C）的当前选择
Curr Vasc Pharmacol. 2021;19(4):398-402. doi: 10.2174/157016111904210216104403.
6
Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP).急性冠状动脉综合征后降脂治疗的最佳应用：国际脂质专家组（ILEP）认可的立场文件。
Pharmacol Res. 2021 Apr;166:105499. doi: 10.1016/j.phrs.2021.105499. Epub 2021 Feb 17.
7
Lipid-lowering therapies: Better together.降脂疗法：联合使用效果更佳。
Atherosclerosis. 2021 Mar;320:86-88. doi: 10.1016/j.atherosclerosis.2021.01.009. Epub 2021 Jan 12.
8
Filling the gap between Guidelines and Real World in the cardiovascular approach to the diabetic patients: the need for a call to action.填补糖尿病患者心血管疾病治疗指南与现实世界之间的差距：需要采取行动呼吁。
Int J Cardiol. 2021 Apr 15;329:205-207. doi: 10.1016/j.ijcard.2020.12.074. Epub 2020 Dec 31.
9
How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors.在二级预防中，LDL 胆固醇应该降低多少？PCSK9 抑制剂时代的临床疗效和安全性。
Prog Cardiovasc Dis. 2021 Jul-Aug;67:65-74. doi: 10.1016/j.pcad.2020.12.008. Epub 2020 Dec 28.
10
Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect.在2型糖尿病患者的真实世界中，利拉鲁肽通过降低小而密低密度脂蛋白来减少颈动脉内膜中层厚度：一种新的抗动脉粥样硬化作用。
Diabetes Ther. 2021 Jan;12(1):261-274. doi: 10.1007/s13300-020-00962-3. Epub 2020 Nov 18.
Zotero 插件